Reply to correspondence on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023” Jeayeon Park, Su Jong Yu Clinical and Molecular Hepatology.2025; 31(2): e221. CrossRef
Neonatal liver-derived FTH1-enriched extracellular vesicles attenuate ferroptosis and ameliorate MASLD pathogenesis Xin Zeng, Wei Jiang, Tian Wu, Lan Li, Fudong Fu, Han Yao, Dongbo Wu Free Radical Biology and Medicine.2025; 240: 693. CrossRef
Liver-Related COVID-19 Consequences: Dynamics of Liver Health in 2.5 Years Ieva Vanaga, Oksana Kolesova, Aleksandrs Kolesovs, Maija Radzina, Davis Simanis Putrins, Jelena Egle, Sniedze Laivacuma, Jelena Storozenko, Ludmila Viksna Journal of Clinical Medicine.2025; 14(21): 7604. CrossRef
Prevalence of MASLD and fibrosis assessed by transient elastography in U.S. adolescents: insights from NHANES 2017-2023 Jialin Wu, Junlong Huang, Shiyu Cao, Yang Lyu, Peiyao Yu, Tiejun Feng, Bonan Chen, Fuda Xie, Ge Zhang, Kangmin Zhuang, Aimin Li, Ka Fai To, Wei Kang Diabetology & Metabolic Syndrome.2025;[Epub] CrossRef
The burden of steatotic liver disease before and during the COVID-19 pandemic: Correspondence to editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023” Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed Clinical and Molecular Hepatology.2025; 31(2): e183. CrossRef
Reply to correspondence on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023” Jeayeon Park, Su Jong Yu Clinical and Molecular Hepatology.2025; 31(2): e221. CrossRef
Kwanjoo Lee, Jaeyu Park, Jinseok Lee, Myeongcheol Lee, Hyeon Jin Kim, Yejun Son, Sang Youl Rhee, Lee Smith, Masoud Rahmati, Jiseung Kang, Hayeon Lee, Yeonjung Ha, Dong Keon Yon
Clin Mol Hepatol 2024;30(4):943-958. Published online August 29, 2024
Background/Aims Considering emerging evidence on long COVID, comprehensive analyses of the post-acute complications of SARS-CoV-2 infection in the gastrointestinal and hepatobiliary systems are needed. We aimed to investigate the impact of COVID-19 on the long-term risk of gastrointestinal and hepatobiliary diseases and other digestive abnormalities.
Methods We used three large-scale population-based cohorts: the Korean cohort (discovery cohort), the Japanese cohort (validation cohort-A), and the UK Biobank (validation cohort-B). A total of 10,027,506 Korean, 12,218,680 Japanese, and 468,617 UK patients aged ≥20 years who had SARS-CoV-2 infection between 2020 and 2021 were matched to non-infected controls. Seventeen gastrointestinal and eight hepatobiliary outcomes as well as nine other digestive abnormalities following SARS-CoV-2 infection were identified and compared with controls.
Result s: The discovery cohort revealed heightened risks of gastrointestinal diseases (HR 1.15; 95% CI 1.08–1.22), hepatobiliary diseases (HR 1.30; 95% CI 1.09–1.55), and other digestive abnormalities (HR 1.05; 95% CI 1.01–1.10) beyond the first 30 days of infection, after exposure-driven propensity score-matching. The risk was pronounced according to the COVID-19 severity. The SARS-CoV-2 vaccination was found to lower the risk of gastrointestinal diseases but did not affect hepatobiliary diseases and other digestive disorders. The results derived from validation cohorts were consistent. The risk profile was most pronounced during the initial 3 months; however, it persisted for >6 months in validation cohorts, but not in the discovery cohort.
Conclusions The incidence of gastrointestinal disease, hepatobiliary disease, and other digestive abnormalities increased in patients with SARS-CoV-2 infection during the post-acute phase.
Citations
Citations to this article as recorded by
Clinical features and inflammatory signatures of patients with persistent gastrointestinal long COVID two years after severe SARS-CoV-2 infection Arlene dos Santos Pinto, Victor Irungu Mwangi, Juliana Costa Ferreira Neves, Alex Bezerra Silva Maciel, Alexandre V. Neto, Jefferson da Silva Valente, Gisely Cardoso de Melo, Wuelton Marcelo Monteiro, Vanderson de Souza Sampaio, Allyson Guimarães da Costa Scientific Reports.2026;[Epub] CrossRef
Long-term effectiveness on glycemic control of insulin compared to combined oral antidiabetic drugs for initial intensive treatment in newly diagnosed type 2 diabetes: A duplicated target trial Tae Hyeon Kim, Yerin Hwang, Selin Woo, Kyeongmin Lee, Yejun Son, Seoyoung Park, Hyunjee Kim, Ju-Young Shin, YongHyun Cho, Dahye Shin, Dosang Cho, Kyung-Jae Lee, Sang Youl Rhee, Dong Keon Yon Medicine.2026; 105(5): e47235. CrossRef
Reply to correspondence on “Long-term gastrointestinal and hepatobiliary outcomes of COVID-19: A multinational population-based cohort study from South Korea, Japan, and the UK” Yang-Hyun Baek Clinical and Molecular Hepatology.2025; 31(1): e123. CrossRef
Correspondence to editorial on “Long-term gastrointestinal and hepatobiliary outcomes of COVID-19: a multinational population-based cohort study from South Korea, Japan, and the UK” Kwanjoo Lee, Jaeyu Park, Jinseok Lee, Hayeon Lee, Yeonjung Ha, Dong Keon Yon Clinical and Molecular Hepatology.2025; 31(1): e87. CrossRef
Understanding the impact on digestive disease in the post-COVID-19 condition: Editorial on “Long-term gastrointestinal and hepatobiliary outcomes of COVID-19: A multinational population-based cohort study from South Korea, Japan, and the UK” Yang-Hyun Baek Clinical and Molecular Hepatology.2025; 31(1): 319. CrossRef
Artificial intelligence models predicting abnormal uterine bleeding after COVID-19 vaccination Yunjeong Choi, Jaeyu Park, Hyejun Kim, Young Joo Lee, Yongbin Lee, Yong Sung Choi, Seung Geun Yeo, Jiseung Kang, Masoud Rahmati, Hayeon Lee, Dong Keon Yon, Jinseok Lee Scientific Reports.2025;[Epub] CrossRef
COVID-19 and Its Effects on the Hepatobiliary System: A Literature Review Sariya Khan, Jumana Hussain Timraz, Nourah A Al Ghamdi, Nada Y Metwali, Faten A Yaseen, Albatool M Alshaqha, Sarah H Alamri, Heba Turkistani, Anas Dwaima, Ibraheem Ali Algarni Cureus.2025;[Epub] CrossRef
Expression of SARS-CoV-2 entry receptor ACE2 in human brain and its association with Alzheimer’s disease and COVID-19 Sijie Li, Jingyi Sun, He Li, Zhifa Han, Tao Wang, Shan Gao, Ping Zhu, Yan Chen, Peiguang Yan, Mingxin Wang, Guiyou Liu Molecular Psychiatry.2025; 30(7): 3257. CrossRef
Post‐Acute Sequelae of COVID‐19 on Alopecia Areata in Individuals With Mental Illness in South Korea and Japan: A Binational Population‐Based Cohort Study Jaehyeong Cho, Jaeyu Park, Yejun Son, Soeun Kim, Hyesu Jo, Seoyeon Kyung, Hayeon Lee, Dong Keon Yon Journal of Medical Virology.2025;[Epub] CrossRef
Postacute Sequelae of COVID‐19 Across 12 Major Health Domains and 141 Diseases in Individuals With Mental Illness Among COVID‐19 Survivors: A Population‐Based Cohort Study in South Korea Jiseung Kang, Jaeyu Park, Yejun Son, Hyeon Jin Kim, Guillaume Fond, Laurent Boyer, Masoud Rahmati, Hayeon Lee, Dong Keon Yon Journal of Medical Virology.2025;[Epub] CrossRef
Global and Regional Burden of Vaccine‐Associated Transverse Myelitis and Potentially Associated With Vaccines From 1967 to 2023: An Analysis of the International Pharmacovigilance Data Jae E. Lee, Hyesu Jo, Hanseul Cho, Jiyeon Oh, Yi Deun Jeong, Sooji Lee, Jaeyu Park, Hyeon Jin Kim, Yejun Son, Soeun Kim, Hayeon Lee, Louis Jacob, Damiano Pizzol, Ho Geol Woo, Jiyoung Hwang, Dong Keon Yon Journal of Medical Virology.2025;[Epub] CrossRef
A Case Definition of a New Disease: A Review of the US Working Definition (USG) and 2024 NASEM Definition for Long COVID Elisa Perego COVID.2025; 5(8): 135. CrossRef
Live zoster vaccination and hepatobiliary risk reduction: a nationwide South Korean study Junyeol Kim, Kyeongmin Lee, Jiyeon Oh, Hayeon Lee, Jong-In Chang, Tae Young Park, Dong Keon Yon, Hyoung-Chul Oh The Korean Journal of Internal Medicine.2025; 40(5): 747. CrossRef
Burden of post-acute sequelae of COVID-19 in patients with type 2 diabetes: a binational cohort study in South Korea and Japan Jiyeon Oh, Soeun Kim, Hyesu Jo, Jaeyu Park, Yejun Son, Sooji Lee, Jinseok Lee, Lee Smith, Jiseung Kang, Junyang Jung, Hayeon Lee, Dong Keon Yon International Journal of Infectious Diseases.2025; 161: 108143. CrossRef
Global burden of vaccine-associated Guillain-Barré syndrome over 170 countries from 1967 to 2023 Yi Deun Jeong, Seoyoung Park, Sooji Lee, Woojin Jang, Jaeyu Park, Kyeongmin Lee, Jinseok Lee, Jiseung Kang, Raphael Udeh, Masoud Rahmati, Seung Geun Yeo, Lee Smith, Hayeon Lee, Dong Keon Yon Scientific Reports.2024;[Epub] CrossRef
Sex-Specific Trends in the Prevalence of Osteoarthritis and Rheumatoid Arthritis From 2005 to 2021 in South Korea: Nationwide Cross-Sectional Study Seoyoung Park, Yejun Son, Hyeri Lee, Hayeon Lee, Jinseok Lee, Jiseung Kang, Lee Smith, Masoud Rahmati, Elena Dragioti, Mark A Tully, Guillaume Fond, Laurent Boyer, Jun Hyuk Lee, Damiano Pizzol, Jaeyu Park, Selin Woo, Dong Keon Yon JMIR Public Health and Surveillance.2024; 10: e57359. CrossRef
Global Estimates of Vaccine-Associated Hepatic Autoimmune Disorders and Their Related Vaccines, 1968–2024: An International Analysis of the WHO Pharmacovigilance Database Jinyoung Jeong, Hyesu Jo, Jaeyu Park, Lee Smith, Masoud Rahmati, Kwanjoo Lee, Yeonjung Ha, Dong Keon Yon International Archives of Allergy and Immunology.2024; 186(7): 696. CrossRef
Correspondence on Letter regarding “COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis” Ka Shing Cheung, Chiu Hang Mok, Wai Kay Seto, Man Fung Yuen Clinical and Molecular Hepatology.2023; 29(1): 176. CrossRef
Correspondence on Letter regarding “COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis” Ka Shing Cheung, Chiu Hang Mok, Wai Kay Seto, Man Fung Yuen Clinical and Molecular Hepatology.2023; 29(1): 176. CrossRef
SARS-CoV-2 and chronic hepatitis B: Focusing on the possible consequences of co-infection Shahrzad Shoraka, Seyed Reza Mohebbi, Seyed Masoud Hosseini, Amir Ghaemi, Mohammad Reza Zali Journal of Clinical Virology Plus.2023; 3(4): 100167. CrossRef
Post-COVID-19 cholangiopathy: Systematic review Mazen Abdalla Rasheed, Vinícius Remus Ballotin, Lucas Goldmann Bigarella, Jonathan Soldera World Journal of Methodology.2023; 13(4): 296. CrossRef
Correspondence on Letter regarding “COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis” Ka Shing Cheung, Chiu Hang Mok, Wai Kay Seto, Man Fung Yuen Clinical and Molecular Hepatology.2023; 29(1): 176. CrossRef
Post-COVID-19 cholangiopathy: Systematic review Mazen Abdalla Rasheed, Vinícius Remus Ballotin, Lucas Goldmann Bigarella, Jonathan Soldera World Journal of Methodology.2023; 13(4): 296. CrossRef
Forms of cholangitis to be considered after SARS-CoV-2 infection Ju-Yeon Cho, Young-Sun Lee, Soon Sun Kim, Do Seon Song, Jeong-Hoon Lee, Ji Hoon Kim Clinical and Molecular Hepatology.2022; 28(4): 929. CrossRef
Background/Aims Data of coronavirus disease 2019 (COVID-19) vaccine immunogenicity among chronic liver disease (CLD) and liver transplant (LT) patients are conflicting. We performed meta-analysis to examine vaccine immunogenicity regarding etiology, cirrhosis status, vaccine platform and type of antibody.
Methods We collected data via three databases from inception to February 16, 2022, and reported pooled seroconversion rate, T cell response and safety data after two vaccine doses.
Result s: Twenty-eight (CLD only: 5; LT only: 18; both: 2; LT with third dose: 3) observational studies of 3,945 patients were included. For CLD patients, seroconversion rate ranged between 84% (95% confidence interval [CI], 76–90%) and 91% (95% CI, 83–95%), based predominantly on neutralizing antibody and anti-spike antibody, respectively. Seroconversion rate was 81% (95% CI, 76–86%) in chronic hepatitis B, 96% (95% CI, 93–97%) in non-alcoholic fatty liver disease, 85% (95% CI, 75–91%) in cirrhosis and 85% (95% CI, 78–90%) in non-cirrhosis, 86% (95% CI, 78–92%) for inactivated vaccine and 89% (95% CI, 71–96%) for mRNA vaccine. The pooled seroconversion rate of anti-spike antibody was 66% (95% CI, 55–75%) after two doses of mRNA vaccines and 88% (95% CI, 58–98%) after third dose among LT recipients. T cell response rate was 65% (95% CI, 30–89%). Prevalence of adverse events was 27% (95% CI, 18–38%) and 63% (95% CI, 39–82%) among CLD and LT groups, respectively.
Conclusions CLD patients had good humoral response to COVID-19 vaccine, while LT recipients had lower response.
Citations
Citations to this article as recorded by
High Rate of Antibody Response to Multiple Doses of the COVID-19 Vaccine in Liver Transplant Recipients: Analysis of Predictive Factors Nunzio Zignani, Andrea Costantino, Michele Sagasta, Clara Dibenedetto, Riccardo Perbellini, Sara Uceda Renteria, Pietro Lampertico, Maria Francesca Donato Vaccines.2025; 13(4): 352. CrossRef
Examining Vaccination Coverage in Patients with Diagnosis of Chronic Liver Disease and Cirrhosis: A Cross-Sectional Study in Greece Paschalina Dafnou, Ioannis Elefsiniotis, Theodoula Adamakidou, Nikoletta Margari, Stelios Parissopoulos, Lambrini Kourkouta, Konstantinos Giakoumidakis, Eleni Dokoutsidou Livers.2025; 5(4): 68. CrossRef
Clinical application of COVID-19 vaccine in liver transplant recipients Feng-Chao Liu, Man Xie, Wei Rao Hepatobiliary & Pancreatic Diseases International.2024; 23(4): 339. CrossRef
Clinical characteristics and outcomes of liver transplant recipients infected by Omicron during the opening up of the dynamic zero-coronavirus disease policy in China: A prospective, observational study Wei Zhang, Rongrong Wang, Pingbo Jin, Xinyu Yu, Weili Wang, Yuntao Zhang, Xueli Bai, Tingbo Liang American Journal of Transplantation.2024; 24(4): 631. CrossRef
Ursodeoxycholic acid does not affect the clinical outcome of SARS‐CoV‐2 infection: A retrospective study of propensity score‐matched cohorts Giuseppe Marrone, Marcello Covino, Giuseppe Merra, Andrea Piccioni, Annamaria Amodeo, Angela Novelli, Rita Murri, Maurizio Pompili, Antonio Gasbarrini, Francesco Franceschi Liver International.2024; 44(1): 83. CrossRef
Effect of ursodeoxycholic acid on preventing SARS-CoV-2 infection in patients with liver transplantation: a multicenter retrospective cohort study L Hu, H Zhang, C Huang, T Shen, Z Feng, F Mu, L Xu, Y Lin, C Yue, K Guo, M Tian, J Shi, C Zhang, P Wen, S Cao, Y Wang, J Zhang, X Shi, Z Wang, Y He, X Zhang, X Liu, Y Lv, Z Liu, W Guo, B Wang QJM: An International Journal of Medicine.2024; 117(5): 339. CrossRef
Advancements in Vaccine Strategies for Chronic Liver Disease Patients: Navigating Post-COVID Challenges and Opportunities Samer Al-Dury, Nelly Kanberg Vaccines.2024; 12(2): 197. CrossRef
Third vaccine boosters and anti‐S‐IgG levels: A comparison of homologous and heterologous responses and poor immunogenicity in hepatocellular carcinoma Chih‐Wen Wang, Chung‐Feng Huang, Tyng‐Yuan Jang, Ming‐Lun Yeh, Po‐Cheng Liang, Yu‐Ju Wei, Po‐Yao Hsu, Ching‐I. Huang, Ming‐Yen Hsieh, Yi‐Hung Lin, Jee‐Fu Huang, Chia‐Yen Dai, Wan‐Long Chuang, Ming‐Lung Yu The Kaohsiung Journal of Medical Sciences.2024; 40(5): 477. CrossRef
Klinische Verläufe und Kosten für Hospitalisierungen von COVID-19-Patienten mit potenziell eingeschränktem Immunsystem in Deutschland Dennis Häckl, Marc Pignot, Phi Long Dang, Victoria Lauenroth, Fungwe Jah, Clemens-Martin Wendtner DMW - Deutsche Medizinische Wochenschrift.2024; 149(07): e38. CrossRef
Immunogenicity of COVID-19 vaccines in patients with cirrhosis: A meta-analysis Lichen Ouyang, Gang Lei, Yeli Gong Human Vaccines & Immunotherapeutics.2024;[Epub] CrossRef
Association between Gut Microbiota Composition and Long-Term Vaccine Immunogenicity following Three Doses of CoronaVac Li-Na Zhang, Jing-Tong Tan, Ho-Yu Ng, Yun-Shi Liao, Rui-Qi Zhang, Kwok-Hung Chan, Ivan Fan-Ngai Hung, Tommy Tsan-Yuk Lam, Ka-Shing Cheung Vaccines.2024; 12(4): 365. CrossRef
Proton pump inhibitors associated with severe COVID‐19 among two‐dose but not three‐dose vaccine recipients Ka Shing Cheung, Vincent K C Yan, Xuxiao Ye, Ivan F N Hung, Esther W Chan, Wai K Leung Journal of Gastroenterology and Hepatology.2024; 39(9): 1837. CrossRef
Serological responses to COVID-19 vaccination in patients with chronic liver diseases Yu-Shan Huang, Szu-Min Hsieh, Feng-Chiao Tsai, Chien-Chih Tung, Hung-Chih Yang, Sui-Yuan Chang, Jann-Tay Wang, Chun-Jen Liu, Tung-Hung Su, Jia-Horng Kao Journal of the Formosan Medical Association.2024; 123(11): 1194. CrossRef
Effect of metabolic dysfunction‐associated steatotic liver disease on BNT162b2 immunogenicity against the severe acute respiratory syndrome coronavirus 2 omicron variant Lok Ka Lam, Jing Tong Tan, Poh Hwa Ooi, Ruiqi Zhang, Kwok Hung Chan, Xianhua Mao, Ivan F N Hung, Wai Kay Seto, Man Fung Yuen, Ka Shing Cheung Journal of Gastroenterology and Hepatology.2024; 39(11): 2386. CrossRef
Letter regarding “COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis” Rujittika Mungmunpuntipantip, Viroj Wiwanitkit Clinical and Molecular Hepatology.2023; 29(1): 168. CrossRef
Correspondence on Letter regarding “COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis” Ka Shing Cheung, Chiu Hang Mok, Wai Kay Seto, Man Fung Yuen Clinical and Molecular Hepatology.2023; 29(1): 176. CrossRef
Impact of chronic liver disease on SARS-CoV-2 infection outcomes: Roles of stage, etiology and vaccination Riccardo Nevola, Livio Criscuolo, Domenico Beccia, Augusto Delle Femine, Rachele Ruocco, Simona Imbriani, Maria Alfano, Angela Villani, Antonio Russo, Pasquale Perillo, Raffaele Marfella, Luigi Elio Adinolfi, Ferdinando Carlo Sasso, Aldo Marrone, Luca Rin World Journal of Gastroenterology.2023; 29(5): 800. CrossRef
Association between Gut Microbiota and SARS-CoV-2 Infection and Vaccine Immunogenicity Ho Yu Ng, Wai K. Leung, Ka Shing Cheung Microorganisms.2023; 11(2): 452. CrossRef
Effect of Moderate to Severe Hepatic Steatosis on Vaccine Immunogenicity against Wild-Type and Mutant Virus and COVID-19 Infection among BNT162b2 Recipients Ka Shing Cheung, Lok Ka Lam, Xianhua Mao, Jing Tong Tan, Poh Hwa Ooi, Ruiqi Zhang, Kwok Hung Chan, Ivan F. N. Hung, Wai Kay Seto, Man Fung Yuen Vaccines.2023; 11(3): 497. CrossRef
Analysis of Antibody Responses After COVID-19 Vaccination in Liver Transplant Recipients: A Single-Center Study Young Ju Oh, Jongman Kim, Eun-Suk Kang, Jinsoo Rhu, Gyu-Seong Choi, Jae-Won Joh Journal of Korean Medical Science.2023;[Epub] CrossRef
Research Progress of Novel Coronavirus Vac-cine in Patients with Chronic Liver Disease 露 王 Advances in Clinical Medicine.2023; 13(04): 6745. CrossRef
Humoral Immune Response after COVID-19 mRNA Vaccination in Patients with Liver Cirrhosis: A Prospective Real-Life Single Center Study Elisa Biliotti, Alessandro Caioli, Chiara Sorace, Raffaella Lionetti, Eugenia Milozzi, Chiara Taibi, Ubaldo Visco Comandini, Fabrizio Maggi, Vincenzo Puro, Gianpiero D’Offizi Biomedicines.2023; 11(5): 1320. CrossRef
COVID‑19 vaccination in liver transplant recipients (Review) Aikaterini Gkoufa, Maria Saridaki, Vasiliki Georgakopoulou, Demetrios Spandidos, Evangelos Cholongitas Experimental and Therapeutic Medicine.2023;[Epub] CrossRef
Meta‐analysis of the immunogenicity of standard and booster SARS‐CoV‐2 vaccination in patients with chronic liver disease and post‐liver transplantation Wen‐Xin Wang, Jitao Wang, Rui Jia, Silvia Martini, Jiaye Liu, Yifei Huang, Fu‐Sheng Wang, Xiaolong Qi, Junliang Fu Portal Hypertension & Cirrhosis.2023; 2(2): 61. CrossRef
Mycophenolate Interruption Restores Anti-SARS-CoV-2 Vaccine Immunogenicity in Unresponsive Liver Transplant Recipients Pierluigi Toniutto, Annarosa Cussigh, Sara Cmet, Martina Fabris, Francesco Curcio, Davide Bitetto, Ezio Fornasiere, Elisa Fumolo, Edmondo Falleti Vaccines.2023; 11(7): 1165. CrossRef
The vaccine-response in patients with cirrhosis after COVID-19 vaccination: A systematic analysis of 168,245 patients with cirrhosis Zheng Li, Yue Hu, Bingwen Zou Journal of Hepatology.2023; 79(4): e157. CrossRef
Research landscape on COVID-19 and liver dysfunction: A bibliometric analysis Sa'ed H Zyoud World Journal of Gastroenterology.2023; 29(27): 4356. CrossRef
Susceptibility to SARS-CoV-2 Infection and Immune Responses to COVID-19 Vaccination Among Recipients of Solid Organ Transplants Vijay Subramanian The Journal of Infectious Diseases.2023; 228(Supplement): S34. CrossRef
Metabolic Associated Fatty Liver Disease (MAFLD) and COVID-19 Infection: An Independent Predictor of Poor Disease Outcome? Vladimir Milivojević, Jelena Bogdanović, Ivana Babić, Nevena Todorović, Ivan Ranković Medicina.2023; 59(8): 1438. CrossRef
Antibiotic Use Prior to COVID-19 Vaccine Is Associated with Higher Risk of COVID-19 and Adverse Outcomes: A Propensity-Scored Matched Territory-Wide Cohort Ka Shing Cheung, Vincent K. C. Yan, Lok Ka Lam, Xuxiao Ye, Ivan F. N. Hung, Esther W. Chan, Wai K. Leung Vaccines.2023; 11(8): 1341. CrossRef
COVID-19 and Liver Disease: An Evolving Landscape Kai Zhu, Olivia Tsai, Daljeet Chahal, Trana Hussaini, Eric M. Yoshida Seminars in Liver Disease.2023; 43(03): 351. CrossRef
Factors influencing immunogenicity and safety of SARS-CoV-2 vaccine in liver transplantation recipients: a systematic review and meta-analysis Xinyi Luo, Fabrice Yves Ndjana Lessomo, Zhimin Yu, Yong Xie Frontiers in Immunology.2023;[Epub] CrossRef
Impact of SARS-CoV-2 Infection on Humoral and Cellular Immunity in a Cohort of Vaccinated Solid Organ Transplant Recipients Bernardo Ayala-Borges, Miguel Escobedo, Natalia Egri, Sabina Herrera, Marta Crespo, Sonia Mirabet, Carlos Arias-Cabrales, Anna Vilella, Eduard Palou, María M. Mosquera, Mariona Pascal, Jordi Colmenero, Marta Farrero, Marta Bodro Vaccines.2023; 11(12): 1845. CrossRef
COVID-19 vaccine and hepatitis: A mini review Beuy Joob, Viroj Wiwanitkit Indian Journal of Allergy, Asthma and Immunology.2023; 37(2): 37. CrossRef
Background/Aims Studies of hepatic steatosis (HS) effect on COVID-19 vaccine immunogenicity are lacking. We aimed to compare immunogenicity of BNT162b2 and CoronaVac among moderate/severe HS and control subjects.
Methods Two hundred ninety-five subjects who received BNT162b2 or CoronaVac vaccines from five vaccination centers were categorized into moderate/severe HS (controlled attenuation parameter ≥268 dB/m on transient elastography) (n=74) or control (n=221) groups. Primary outcomes were seroconversion rates of neutralising antibody by live virus Microneutralization (vMN) assay (titer ≥10) at day21 (BNT162b2) or day28 (CoronaVac) and day56 (both). Secondary outcome was highest-tier titer response (top 25% of vMN titer; cutoff: 160 [BNT162b2] and 20 [CoronaVac]) at day 56.
Result s: For BNT162b2 (n=228, 77.3%), there was no statistical differences in seroconversion rates (day21: 71.7% vs. 76.6%; day56: 100% vs. 100%) or vMN geometric mean titer (GMT) (day21: 13.2 vs. 13.3; day56: 91.9 vs. 101.4) among moderate/severe HS and control groups respectively. However, lower proportion of moderate/severe HS patients had highest-tier response (day56: 5.0% vs. 15.5%; P=0.037). For CoronaVac (n=67, 22.7%), there was no statistical differences in seroconversion rates (day21: 7.1% vs. 15.1%; day56: 64.3% vs. 83.0%) or vMN GMT (5.3 vs. 5.8,) at day28. However, moderate/severe HS patients had lower vMN GMT (9.1 vs. 14.8, P=0.021) at day 56 with lower proportion having highest-tier response (21.4% vs. 52.8%, P=0.036).
Conclusions While there was no difference in seroconversion rate between moderate/severe HS and control groups after two doses of vaccine, a lower proportion of moderate/severe HS patients achieved highest-tier response for either BNT162b2 or CoronaVac.
Citations
Citations to this article as recorded by
Gut microbiota is associated with persistence of longer-term BNT162b2 vaccine immunogenicity Ho Yu Ng, Yunshi Liao, Ching Lung Cheung, Ruiqi Zhang, Kwok Hung Chan, Wai-Kay Seto, Wai K. Leung, Ivan F. N. Hung, Tommy T. Y. Lam, Ka Shing Cheung Frontiers in Immunology.2025;[Epub] CrossRef
Association between Gut Microbiota Composition and Long-Term Vaccine Immunogenicity following Three Doses of CoronaVac Li-Na Zhang, Jing-Tong Tan, Ho-Yu Ng, Yun-Shi Liao, Rui-Qi Zhang, Kwok-Hung Chan, Ivan Fan-Ngai Hung, Tommy Tsan-Yuk Lam, Ka-Shing Cheung Vaccines.2024; 12(4): 365. CrossRef
Effects of empagliflozin on liver fat in patients with metabolic dysfunction–associated steatotic liver disease without diabetes mellitus: A randomized, double-blind, placebo-controlled trial Ka Shing Cheung, Ho Yu Ng, Rex Wan Hin Hui, Lok Ka Lam, Lung Yi Mak, Yuen Chi Ho, Jing Tong Tan, Esther W. Chan, Wai Kay Seto, Man Fung Yuen, Wai K. Leung Hepatology.2024; 80(4): 916. CrossRef
Proton pump inhibitors associated with severe COVID‐19 among two‐dose but not three‐dose vaccine recipients Ka Shing Cheung, Vincent K C Yan, Xuxiao Ye, Ivan F N Hung, Esther W Chan, Wai K Leung Journal of Gastroenterology and Hepatology.2024; 39(9): 1837. CrossRef
Effect of metabolic dysfunction‐associated steatotic liver disease on BNT162b2 immunogenicity against the severe acute respiratory syndrome coronavirus 2 omicron variant Lok Ka Lam, Jing Tong Tan, Poh Hwa Ooi, Ruiqi Zhang, Kwok Hung Chan, Xianhua Mao, Ivan F N Hung, Wai Kay Seto, Man Fung Yuen, Ka Shing Cheung Journal of Gastroenterology and Hepatology.2024; 39(11): 2386. CrossRef
Long-term antibody response after the third dose of inactivated SARS-CoV-2 vaccine in MASLD patients Jin Cui, Lianbang Wang, Armin Ghavamian, Xuemei Li, Gongzheng Wang, Tao Wang, Min Huang, Qi Ru, Xinya Zhao BMC Gastroenterology.2024;[Epub] CrossRef
Correspondence on Letter regarding “COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis” Ka Shing Cheung, Chiu Hang Mok, Wai Kay Seto, Man Fung Yuen Clinical and Molecular Hepatology.2023; 29(1): 176. CrossRef
Association between Gut Microbiota and SARS-CoV-2 Infection and Vaccine Immunogenicity Ho Yu Ng, Wai K. Leung, Ka Shing Cheung Microorganisms.2023; 11(2): 452. CrossRef
COVID-19 and MAFLD/NAFLD: An updated review Ali Nowroozi, Sara Momtazmanesh, Nima Rezaei Frontiers in Medicine.2023;[Epub] CrossRef
Effect of Moderate to Severe Hepatic Steatosis on Vaccine Immunogenicity against Wild-Type and Mutant Virus and COVID-19 Infection among BNT162b2 Recipients Ka Shing Cheung, Lok Ka Lam, Xianhua Mao, Jing Tong Tan, Poh Hwa Ooi, Ruiqi Zhang, Kwok Hung Chan, Ivan F. N. Hung, Wai Kay Seto, Man Fung Yuen Vaccines.2023; 11(3): 497. CrossRef
Research Progress of Novel Coronavirus Vac-cine in Patients with Chronic Liver Disease 露 王 Advances in Clinical Medicine.2023; 13(04): 6745. CrossRef
SARS-CoV-2 and the liver: clinical and immunological features in chronic liver disease Hendrik Luxenburger, Robert Thimme Gut.2023; 72(9): 1783. CrossRef
COVID-19 and Fatty Liver Disorders Maria Guarino, Valentina Cossiga, Francesco Cutolo, Maria Attanasio, Raffaele Lieto, Filomena Morisco Journal of Clinical Medicine.2023; 12(13): 4316. CrossRef
Antibiotic Use Prior to COVID-19 Vaccine Is Associated with Higher Risk of COVID-19 and Adverse Outcomes: A Propensity-Scored Matched Territory-Wide Cohort Ka Shing Cheung, Vincent K. C. Yan, Lok Ka Lam, Xuxiao Ye, Ivan F. N. Hung, Esther W. Chan, Wai K. Leung Vaccines.2023; 11(8): 1341. CrossRef
Immunogenicity of an mRNA-Based COVID-19 Vaccine among Adolescents with Obesity or Liver Transplants Chomchanat Tubjaroen, Sittichoke Prachuapthunyachart, Nattakoon Potjalongsilp, Pimpayao Sodsai, Nattiya Hirankarn, Peera Jaru-Ampornpan, Voranush Chongsrisawat Vaccines.2022; 10(11): 1867. CrossRef
Correspondence on Letter regarding “COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis” Ka Shing Cheung, Chiu Hang Mok, Wai Kay Seto, Man Fung Yuen Clinical and Molecular Hepatology.2023; 29(1): 176. CrossRef
SARS-CoV-2 Infection and Liver Disease: A Review of Pathogenesis and Outcomes Luke Baldelli, Thomas Marjot, Eleanor Barnes, A. Sidney Barritt, Gwilym J. Webb, Andrew M. Moon Gut and Liver.2023; 17(1): 12. CrossRef
Analysis of Antibody Responses After COVID-19 Vaccination in Liver Transplant Recipients: A Single-Center Study Young Ju Oh, Jongman Kim, Eun-Suk Kang, Jinsoo Rhu, Gyu-Seong Choi, Jae-Won Joh Journal of Korean Medical Science.2023;[Epub] CrossRef
Acute Budd‐Chiari syndrome with thrombotic thrombocytopenia after BNT162b2 mRNA vaccination Pil S. Sung, Jung S. Oh, Joon‐Il Choi Liver International.2022; 42(6): 1447. CrossRef
Forms of cholangitis to be considered after SARS-CoV-2 infection Ju-Yeon Cho, Young-Sun Lee, Soon Sun Kim, Do Seon Song, Jeong-Hoon Lee, Ji Hoon Kim Clinical and Molecular Hepatology.2022; 28(4): 929. CrossRef
Autoimmune liver disease represented as primary biliary cholangitis after SARS-CoV-2 infection: A need for population-based cohort study Soon Kyu Lee, Jung Hyun Kwon, Nara Yoon, Soon Woo Nam, Pil Soo Sung Clinical and Molecular Hepatology.2022; 28(4): 926. CrossRef
Yu Rim Lee, Min Kyu Kang, Jeong Eun Song, Hyun Jung Kim, Young Oh Kweon, Won Young Tak, Se Young Jang, Jung Gil Park, Changhyeong Lee, Jae Seok Hwang, Byoung Kuk Jang, Jeong Ill Suh, Woo Jin Chung, Byung Seok Kim, Soo Young Park
Clin Mol Hepatol 2020;26(4):562-576. Published online October 1, 2020
Background/Aims Although coronavirus disease 2019 (COVID-19) has spread rapidly worldwide, the implication of pre-existing liver disease on the outcome of COVID-19 remains unresolved.
Methods A total of 1,005 patients who were admitted to five tertiary hospitals in South Korea with laboratory-confirmed COVID-19 were included in this study. Clinical outcomes in COVID-19 patients with coexisting liver disease as well as the predictors of disease severity and mortality of COVID-19 were assessed.
Result s: Of the 47 patients (4.7%) who had liver-related comorbidities, 14 patients (1.4%) had liver cirrhosis. Liver cirrhosis was more common in COVID-19 patients with severe pneumonia than in those with non-severe pneumonia (4.5% vs. 0.9%, P=0.006). Compared to patients without liver cirrhosis, a higher proportion of patients with liver cirrhosis required oxygen therapy; were admitted to the intensive care unit; had septic shock, acute respiratory distress syndrome, or acute kidney injury; and died (P<0.05). The overall survival rate was significantly lower in patients with liver cirrhosis than in those without liver cirrhosis (log-rank test, P=0.003). Along with old age and diabetes, the presence of liver cirrhosis was found to be an independent predictor of severe disease (odds ratio, 4.52; 95% confidence interval [CI], 1.20–17.02;P=0.026) and death (hazard ratio, 2.86; 95% CI, 1.04–9.30; P=0.042) in COVID-19 patients.
Conclusions This study suggests liver cirrhosis is a significant risk factor for COVID-19. Stronger personal protection and more intensive treatment for COVID-19 are recommended in these patients.
Citations
Citations to this article as recorded by
Global geographic and socioeconomic disparities in COVID-associated acute kidney injury: a systematic review and meta-analysis Danyang Dai, Pedro Franca Gois, Digby Simpson, Souhayel Hedfi, Sally Shrapnel, Jason Donald Pole Journal of Global Health.2025;[Epub] CrossRef
Risk Factors of Severe COVID-19: A Review of Host, Viral and Environmental Factors Levente Zsichla, Viktor Müller Viruses.2023; 15(1): 175. CrossRef
SARS-CoV-2 induced liver injury: Incidence, risk factors, impact on COVID-19 severity and prognosis in different population groups George D Liatsos World Journal of Gastroenterology.2023; 29(16): 2397. CrossRef
COVID-19 and severity of liver diseases: Possible crosstalk and clinical implications Mohammad T. Imam, Ziyad S. Almalki, Abdullah R. Alzahrani, Saeed S. Al-Ghamdi, Alaa H. Falemban, Ibrahim M. Alanazi, Naiyer Shahzad, Munira Muhammad Alrooqi, Qaiser Jabeen, Imran Shahid International Immunopharmacology.2023; 121: 110439. CrossRef
Clinical Effect of Hepatitis B Virus on COVID-19 Infected Patients: A Nationwide Population-Based Study Using the Health Insurance Review & Assessment Service Database Jung Wan Choe, Young Kul Jung, Hyung Joon Yim, Gi Hyeon Seo Journal of Korean Medical Science.2022;[Epub] CrossRef
Heterogeneity and Risk of Bias in Studies Examining Risk Factors for Severe Illness and Death in COVID-19: A Systematic Review and Meta-Analysis Abraham Degarege, Zaeema Naveed, Josiane Kabayundo, David Brett-Major Pathogens.2022; 11(5): 563. CrossRef
COVID-19 Severity and Mortality Among Chronic Liver Disease Patients: A Systematic Review and Meta-Analysis Ramya Nagarajan, Yuvaraj Krishnamoorthy, Sathish Rajaa, Vishnu Shankar Hariharan Preventing Chronic Disease.2022;[Epub] CrossRef
Forms of cholangitis to be considered after SARS-CoV-2 infection Ju-Yeon Cho, Young-Sun Lee, Soon Sun Kim, Do Seon Song, Jeong-Hoon Lee, Ji Hoon Kim Clinical and Molecular Hepatology.2022; 28(4): 929. CrossRef
A systems biology approach for investigating significantly expressed genes among COVID-19, hepatocellular carcinoma, and chronic hepatitis B Babak Sokouti Egyptian Journal of Medical Human Genetics.2022;[Epub] CrossRef
Autoimmune liver disease represented as primary biliary cholangitis after SARS-CoV-2 infection: A need for population-based cohort study Soon Kyu Lee, Jung Hyun Kwon, Nara Yoon, Soon Woo Nam, Pil Soo Sung Clinical and Molecular Hepatology.2022; 28(4): 926. CrossRef
Prognostic Impact of Myosteatosis on Mortality in Hospitalized Patients with COVID-19 Min-Kyu Kang, Yu-Rim Lee, Jeung-Eun Song, Young-Oh Kweon, Won-Young Tak, Se-Young Jang, Jung-Gil Park, Soo-Young Park Diagnostics.2022; 12(9): 2255. CrossRef
The association of chronic liver disorders with exacerbation of symptoms and complications related to COVID‐19: A systematic review and meta‐analysis of cohort studies Maryam Afraie, Pardis Mohammadzedeh, Mobin Azami, Sorour Khateri, Kamran Zamani, Farhad Moradpour, Yousef Moradi The Clinical Respiratory Journal.2022; 16(12): 777. CrossRef
COVID-19 With Preexisting Hypercoagulability Digestive Disease Mingshan Jiang, Jingxi Mu, Silan Shen, Hu Zhang Frontiers in Medicine.2021;[Epub] CrossRef
A narrative review on characterization of acute respiratory distress syndrome in COVID-19-infected lungs using artificial intelligence Jasjit S. Suri, Sushant Agarwal, Suneet K. Gupta, Anudeep Puvvula, Mainak Biswas, Luca Saba, Arindam Bit, Gopal S. Tandel, Mohit Agarwal, Anubhav Patrick, Gavino Faa, Inder M. Singh, Ronald Oberleitner, Monika Turk, Paramjit S. Chadha, Amer M. Johri, J. M Computers in Biology and Medicine.2021; 130: 104210. CrossRef
COVID‐19 in hospitalized liver transplant recipients: An early systematic review and meta‐analysis Kumar Jayant, Isabella Reccia, Francesco Virdis, Jordan S. Pyda, Piotr J. Bachul, Diego di Sabato, Rolf N. Barth, John Fung, Talia Baker, Piotr Witkowski Clinical Transplantation.2021;[Epub] CrossRef
Management of Patients with Chronic Liver Disease: The Era of the COVID-19 Pandemic Yu Rim Lee The Korean Journal of Gastroenterology.2021; 77(4): 156. CrossRef
Patients with cirrhosis during the COVID-19 pandemic: Current evidence and future perspectives Hung-Yuan Su, Yin-Chou Hsu World Journal of Clinical Cases.2021; 9(13): 2951. CrossRef
Italian association for the study of the liver position statement on SARS-CoV2 vaccination Francesco Paolo Russo, Salvatore Piano, Raffaele Bruno, Patrizia Burra, Massimo Puoti, Mario Masarone, Sara Montagnese, Francesca Romana Ponziani, Salvatore Petta, Alessio Aghemo Digestive and Liver Disease.2021; 53(6): 677. CrossRef
Angiotensin-converting enzyme 2 receptors, chronic liver diseases, common medications, and clinical outcomes in coronavirus disease 2019 patients Wattana Leowattana World Journal of Virology.2021; 10(3): 86. CrossRef
Impact of COVID-19 on liver Yu-Jang Su, Chen-Wang Chang, Ming-Jen Chen, Yen-Chun Lai World Journal of Clinical Cases.2021; 9(27): 7998. CrossRef
Update on liver disease management during the pandemic of coronavirus disease 2019 (COVID-19): 2021 KASL guideline Ju-Yeon Cho, Young-Sun Lee, Soon Sun Kim, Do Seon Song, Jeong-Hoon Lee, Ji Hoon Kim Clinical and Molecular Hepatology.2021; 27(4): 515. CrossRef
Clinical outcomes in COVID-19 and cirrhosis: a systematic review and meta-analysis of observational studies Paul Middleton, Catherine Hsu, Mark P Lythgoe BMJ Open Gastroenterology.2021; 8(1): e000739. CrossRef
Multicenter Analysis of Clinical Features and Prognosis of COVID-19 Patients with Hepatic Impairment Jeong Eun Song, Min Kyu Kang, Yu Rim Lee, Chang Hyeong Lee, Jung Gil Park, Young Oh Kweon, Won Young Tak, Soo Young Park, Se Young Jang, Jae Seok Hwang, Byoung Kuk Jang, Won Young Jang, Jeong Ill Suh, Woo Jin Chung, Byung Seok Kim Gut and Liver.2021; 15(4): 606. CrossRef
Critical Update on the Diagnosis and Management of COVID-19 in Advanced Cirrhosis and Liver Transplant Recipients Cyriac Abby Philips, Mohamed Rela, Arvinder Singh Soin, Subhash Gupta, Sudhindran Surendran, Philip Augustine Journal of Clinical and Translational Hepatology.2021; 000(000): 000. CrossRef
Impact of Coronavirus Disease 2019 on Unresectable Hepatocellular Carcinoma Treated with Atezolizumab/Bevacizumab Yun Beom Sang, Chaeryoung Lee, Seul-Gi Kim, Boyoung Lee, Beodeul Kang, Chan Kim, Hong Jae Chon Journal of Clinical Medicine.2024; 13(5): 1335. CrossRef
SARS-CoV-2 Infection and Liver Disease: A Review of Pathogenesis and Outcomes Luke Baldelli, Thomas Marjot, Eleanor Barnes, A. Sidney Barritt, Gwilym J. Webb, Andrew M. Moon Gut and Liver.2023; 17(1): 12. CrossRef
Autoimmune liver disease represented as primary biliary cholangitis after SARS-CoV-2 infection: A need for population-based cohort study Soon Kyu Lee, Jung Hyun Kwon, Nara Yoon, Soon Woo Nam, Pil Soo Sung Clinical and Molecular Hepatology.2022; 28(4): 926. CrossRef
Forms of cholangitis to be considered after SARS-CoV-2 infection Ju-Yeon Cho, Young-Sun Lee, Soon Sun Kim, Do Seon Song, Jeong-Hoon Lee, Ji Hoon Kim Clinical and Molecular Hepatology.2022; 28(4): 929. CrossRef
Management of Patients with Chronic Liver Disease: The Era of the COVID-19 Pandemic Yu Rim Lee The Korean Journal of Gastroenterology.2021; 77(4): 156. CrossRef
Update on liver disease management during the pandemic of coronavirus disease 2019 (COVID-19): 2021 KASL guideline Ju-Yeon Cho, Young-Sun Lee, Soon Sun Kim, Do Seon Song, Jeong-Hoon Lee, Ji Hoon Kim Clinical and Molecular Hepatology.2021; 27(4): 515. CrossRef
Maintaining standard volumes, efficacy and safety, of fecal microbiota transplantation for C. difficile infection during the COVID-19 pandemic: A prospective cohort study Gianluca Ianiro, Stefano Bibbò, Luca Masucci, Gianluca Quaranta, Serena Porcari, Carlo Romano Settanni, Loris Riccardo Lopetuso, Massimo Fantoni, Maurizio Sanguinetti, Antonio Gasbarrini, Giovanni Cammarota Digestive and Liver Disease.2020; 52(12): 1390. CrossRef
First
Prev
